Professor of Pharmacology and Cancer Biology
Associate Professor of Radiation Oncology
Duke University School of Medicine
Durham, NC 27710
We study the molecular mechanisms underlying the process by which the oncogene Ras drives the tumorigenic process. Ras is the most commonly mutated oncogene in human cancer, yet it has so far defied being clinically inhibited. Correspondingly, the lab focuses on identifying new signaling pathways and ultimately druggable proteins used by Ras to promote cancer. In turn, we evaluate whether pharmacologic inhibition of such proteins inhibit cancer, with the goal of translating these findings into clinical trials.